Gå direkt till huvudinnehållet

Effekter av testosteron

Senast uppdaterad: Senast reviderad:

  1. Nieschlag E and Behre HM (Eds). Testosterone. Action, deficiency, substitution. Cambridge University Press, Cambridge, UK 2004.
  2. Bashin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS and Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2006; 91: 1995-2010. PubMed  
  3. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Clinical practice guideline. Androgen therapy in women. An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006; 91: 3697-3710. PubMed  
  4. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001; 22: 718-31. PubMed  
  5. Liverman CT, Blazer DG, eds. Testosterone and aging: clinical research directions. Washington, D.C.: National Academies Press, 2004.
  6. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-98. PubMed  
  7. Svartberg J. Epidemiology – Testosterone and the metabolic syndrome. Int J Impot Res 2007; 19: 124-8. PubMed  
  8. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839-53. PubMed  
  9. Snyder PJ, Bhasin S, Cunningham GR, et al. Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med 2016; Feb 18;374(7): 611-24. pmid:20592293 PubMed  
  10. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86: 3555-61. PubMed  
  11. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386-90. PubMed  
  12. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56: 266-72. PubMed  
  13. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-72. PubMed  
  14. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men. A randomized controlled trial. JAMA 2008: 299: 39-52.
  15. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647-53. PubMed  
  16. Srinivas-Shanker U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-50. PubMed  
  17. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994; 108: 325-32. PubMed  
  18. Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-7. PubMed  
  19. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab 1998; 12: 379-90. PubMed  
  20. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab 2000; 85: 60-5. PubMed  
  21. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000; 57: 141-7. PubMed  
  22. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 2000; 133: 348-55. Annals of Internal Medicine  
  23. Svartberg J, Aasebø U, Hjalmarsen A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD in a 6-month randomized controlled trial. Respir Med 2004; 98: 906-13. PubMed  
  24. Inga säkra bevis för ökad risk för hjärtproblem med testosteronläkemedel. Läkemedelsverket 2014-10-15. www.lakemedelsverket.se  
  25. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49: 191-6. PubMed  
  26. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 1997;19: 383-404. PubMed  
  27. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999; 44: 1012-20. PubMed  
  28. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 1997; 19: 383-404. PubMed  
  29. Rodriguez KM, Pastuszak AW, Khera M.The Role of Testosterone Therapy in the Setting of Prostate Cancer. Send to Curr Urol Rep. 2018 Jun 30;19(8):67. PMID: 29961247 PubMed  
  30. Pharmacovigilance Risk Assessment Committee (PRAC). European Medicines Agency. PRAC review does not confirm increase in heart problems with testosterone medicines. 10/10/2014 www.ema.europa.eu  
  31. Hudson J, Cruickshank M, Quinton R, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. Lancet Healthy Longevity 2022; 3: 381-393. doi:10.1016/S2666-7568(22)00096-4 DOI  
  32. Lincoff AM, Bhasin S, Flevaris P et al; TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 Jun 16. doi: 10.1056/NEJMoa2215025. Epub ahead of print. PMID: 37326322 PubMed  
  33. Walker RF, Zakai NA, MacLehose RF, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA Intern Med 2019. pmid:31710339. www.ncbi.nlm.nih.gov  
  34. Kaplan HS, Owett T. The female androgen deficiency syndrome. J Sex Marital Ther 1993; 19: 3-24. PubMed  
  35. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003; 79: 1341-52. PubMed  
  36. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-8. New England Journal of Medicine  
  37. Jassal SK, Barrett-Connor E, Edelstein SL. Low bioavailable testosterone levels predict future height loss in postmenopausal women. J Bone Miner Res 1995; 10: 650-4. PubMed  
  38. Riley A, Riley E. Controlled studies on women presenting with sexual drive disorder: I. Endocrine status. J Sex Marital Ther 2000; 26: 269-83. PubMed  
  39. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003; 10: 390-8. PubMed  
  40. Noakes TD. Tainted glory-doping and athletic performance. N Engl J Med 2004; 351: 847-9. New England Journal of Medicine  
  41. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St. Clair LS, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005; 62: 154-62. PubMed  
  42. Lawrence ME, Kirby DF. Nutrition and sports supplements: fact or fiction. J Clin Gastroenterol 2002; 35: 299-306. PubMed  
  43. Lombardo JA. Supplements and athletes. South Med J 2004; 97: 877-9. PubMed  
  • Jan-Erik Damber, professor och överläkare, Enheten för urologi, Sahlgrenska universitetssjukhuset, Göteborg